Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/42475
Type
ArticleCopyright
Open access
Sustainable Development Goals
05 Igualdade de gêneroCollections
- IOC - Artigos de Periódicos [12871]
Metadata
Show full item record
EVOLUTION OF THE INNATE AND ADAPTIVE IMMUNE RESPONSE IN WOMEN WITH ACUTE ZIKA VIRUS INFECTION
Author
Tonnerre, Pierre
Melgaço, Juliana G.
Torres-Cornejo, Almudena
Pinto, Marcelo A.
Yue, Constanze
Blümel, Johannes
Sousa, Paulo Sergio Fonseca de
Mello, Vinicius da Motta de
Moran, Julio
Filippis, Ana M. Bispo de
Wolski, David
Grifoni, Alba
Sette, Alessandro
Barouch, Dan H.
Hoogeveen, Ruben C.
Baylis, Sally A.
Lauer, Georg M.
Lewis-Ximenez, Lia L.
Melgaço, Juliana G.
Torres-Cornejo, Almudena
Pinto, Marcelo A.
Yue, Constanze
Blümel, Johannes
Sousa, Paulo Sergio Fonseca de
Mello, Vinicius da Motta de
Moran, Julio
Filippis, Ana M. Bispo de
Wolski, David
Grifoni, Alba
Sette, Alessandro
Barouch, Dan H.
Hoogeveen, Ruben C.
Baylis, Sally A.
Lauer, Georg M.
Lewis-Ximenez, Lia L.
Affilliation
Massachusetts General Hospital and Harvard Medical School, Boston. Division of Gastroenterology. Boston, MA, USA.
Massachusetts General Hospital and Harvard Medical School, Boston. Division of Gastroenterology. Boston, MA, USA / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Massachusetts General Hospital and Harvard Medical School, Boston. Division of Gastroenterology. Boston, MA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Paul-Ehrlich-Institut. Division of Virology. Langen, Germany.
Paul-Ehrlich-Institut. Division of Virology. Langen, Germany.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Dr. Julio Moran Laboratories. Herrliberg, Zurich, Switzerland.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Massachusetts General Hospital and Harvard Medical School, Boston. Division of Gastroenterology. Boston, MA, USA.
La Jolla Institute for Immunology. Division of Vaccine Discovery. La Jolla, CA, USA.
La Jolla Institute for Immunology. Division of Vaccine Discovery. La Jolla, CA, USA / University of California San Diego. Department of Medicine. La Jolla, CA, USA.
Ragon Institute of MGH, MIT and Harvard. Cambridge, MA, USA / Beth Israel Deaconess Medical Center. Center for Virology and Vaccine Research. Boston, MA, USA,
Massachusetts General Hospital and Harvard Medical School, Boston. Division of Gastroenterology. Boston, MA, USA.
Paul-Ehrlich-Institut. Division of Virology. Langen, Germany.
Massachusetts General Hospital and Harvard Medical School, Boston. Division of Gastroenterology. Boston, MA, USA / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Massachusetts General Hospital and Harvard Medical School, Boston. Division of Gastroenterology. Boston, MA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Paul-Ehrlich-Institut. Division of Virology. Langen, Germany.
Paul-Ehrlich-Institut. Division of Virology. Langen, Germany.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Dr. Julio Moran Laboratories. Herrliberg, Zurich, Switzerland.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Massachusetts General Hospital and Harvard Medical School, Boston. Division of Gastroenterology. Boston, MA, USA.
La Jolla Institute for Immunology. Division of Vaccine Discovery. La Jolla, CA, USA.
La Jolla Institute for Immunology. Division of Vaccine Discovery. La Jolla, CA, USA / University of California San Diego. Department of Medicine. La Jolla, CA, USA.
Ragon Institute of MGH, MIT and Harvard. Cambridge, MA, USA / Beth Israel Deaconess Medical Center. Center for Virology and Vaccine Research. Boston, MA, USA,
Massachusetts General Hospital and Harvard Medical School, Boston. Division of Gastroenterology. Boston, MA, USA.
Paul-Ehrlich-Institut. Division of Virology. Langen, Germany.
Abstract
Zika virus (ZIKV) is a flavivirus that is closely related to other human pathogens, such as dengue virus (DENV)1. Primary transmission usually involves Aedes aegypti, which has expanded its distribution range considerably2, although rarer infection routes, including mother-to-fetus transmission, sexual contact and blood transfusion, have also been observed3-7. Primary ZIKV infection is usually asymptomatic or mild in adults, with quickly resolved blood viraemia, but ZIKV might persist for months in saliva, urine, semen, breast milk and the central nervous system8-12. During a recent ZIKV outbreak in South America, substantial numbers of neurological complications, such as Guillain-Barré syndrome, were reported13,14 together with cases of microcephaly and associated developmental problems in infants born to women infected with ZIKV during pregnancy15-20, highlighting the clinical importance of this infection. Analyses of the human immune response to ZIKV are lacking21-28, but the recent outbreak has provided an opportunity to assess ZIKV immunity using current immunological methods. Here, we comprehensively assess the acute innate and adaptive immune response to ZIKV infection in ten women who were recruited during early infection and followed through reconvalescence. We define a cascade of events that lead to immunological control of ZIKV, with previous exposure to DENV impacting some, but not all, mediators of antiviral immunity.
Share